Beta
Company data is growing.
← All companies
/
Top lists
/
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals
2016–2025 · 469 US lab companies
2026-08-05
Overview
Earnings
Margins
Cash flow
Balance
Capital
Plot
Millions
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
—
—
75
220
493
844
1 037
1 828
2 248
3 714
Operating profit (EBIT)
−425
−500
−815
−939
−828
−709
−785
−282
−177
502
Net income attributable to shareholders
−410
−491
−761
−886
−858
−853
−1 131
−440
−278
314
EBIT margin
—
—
—
—
—
−83,9%
−75,7%
−15,4%
−7,9%
13,5%
Gross margin
—
—
—
88,6%
84,2%
86,4%
86,5%
85,3%
86,4%
81,8%
Operating cash flow
−308
−383
−563
−278
−615
−642
−541
104
−8
524
Free cash flow
−372
−487
−690
−419
−685
−718
−613
42
−43
465
Cash
194
645
420
547
497
820
866
813
966
1 657
−2 000
0
2 000
4 000
−100,0%
−50,0%
0,0%
50,0%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
75
220
493
844
1 037
1 828
2 248
3 714
−425
−500
−815
−939
−828
−709
−785
−282
−177
502